Your browser doesn't support javascript.
Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient.
Jaki, Lena; Weigang, Sebastian; Kern, Lisa; Kramme, Stefanie; Wrobel, Antoni G; Grawitz, Andrea B; Nawrath, Philipp; Martin, Stephen R; Dähne, Theo; Beer, Julius; Disch, Miriam; Kolb, Philipp; Gutbrod, Lisa; Reuter, Sandra; Warnatz, Klaus; Schwemmle, Martin; Gamblin, Steven J; Neumann-Haefelin, Elke; Schnepf, Daniel; Welte, Thomas; Kochs, Georg; Huzly, Daniela; Panning, Marcus; Fuchs, Jonas.
  • Jaki L; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Weigang S; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Kern L; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Kramme S; Institute for Infection Prevention and Hospital Epidemiology, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.
  • Wrobel AG; The Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK.
  • Grawitz AB; Institute for Clinical Chemistry and Laboratory Medicine, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Nawrath P; The Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK.
  • Martin SR; The Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK.
  • Dähne T; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Beer J; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Disch M; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Kolb P; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Gutbrod L; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Reuter S; Institute for Infection Prevention and Hospital Epidemiology, Freiburg University Medical Center, University of Freiburg, Freiburg, Germany.
  • Warnatz K; Department of Rheumatology and Clinical Immunology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Schwemmle M; Center for Chronic Immunodeficiency (CCI), Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Gamblin SJ; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Neumann-Haefelin E; The Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London, UK.
  • Schnepf D; Renal Division, Department of Medicine, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Welte T; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Kochs G; Renal Division, Department of Medicine, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Huzly D; Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
  • Panning M; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Fuchs J; Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Nat Commun ; 14(1): 1999, 2023 04 10.
Article in English | MEDLINE | ID: covidwho-2297060
ABSTRACT
Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patient with hypogammaglobulinemia. Following mAb treatment, the patient did not clear the infection. During viral persistence, SARS-CoV-2 acquired three novel spike mutations. Neutralization and mouse protection analyses demonstrate a complete viral escape from REGN-COV at the expense of ACE-2 binding. Final clearance of the virus occurred upon reduction of the immunosuppressive regimen and total IgG substitution. Serology suggests that the development of highly neutralizing IgM rather than IgG substitution aids clearance. Our findings emphasise that selection pressure by mAbs on SARS-CoV-2 can lead to development of escape variants in immunocompromised patients. Thus, modification of immunosuppressive therapy, if possible, might be preferable to control and clearance of the viral infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Variants Limits: Animals Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-023-37591-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study Topics: Variants Limits: Animals Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2023 Document Type: Article Affiliation country: S41467-023-37591-w